Innobio Overview
Bpifrance manages multiple venture capital funds focused on early- and mid-stage biotech and medtech start-ups, investing in promising French life sciences companies up to an IPO or strategic partnership. Key funds include Innobio, Innobio 2, the Rare Diseases Fund, the Medtech Innovation Fund, and Patient Autonome, each targeting specific areas within the biotech and medtech sectors.
Is Innobio the right investor for your startup? Browse their investment focus, stage preferences, and geographic scope to see how well they align with your fundraising goals. Your full match score with Innobio, along with a list of other relevant VCs, is available on Hopohopo.io.
Innobio
Investment focus
Invest in
- Western Europe 1 / 14
Product type
- Software-enabled hardware
- Drugs / Pharma
Industries / verticals
- BioTech & Life Sciences
- MedTech & Devices
Investment role
Lead and follow
Stages
Seed, Series A, Series B or later
First ticket size
€500,000 - €14,000,000
How to approach funds like Innobio
When approaching Bpifrance's biotech and medtech VC funds, founders should highlight strong clinical or technological differentiation and a clear path to regulatory milestones. Demonstrate how your solution addresses unmet medical needs or advances patient outcomes, and be prepared to discuss your strategy for scaling within the French and broader European healthcare ecosystem. Emphasize robust scientific validation, a credible team with sector expertise, and a well-defined plan for leveraging public-private partnerships or non-dilutive funding.
Find the best-fitting investors for your startup
Stop wasting weeks searching for the right investors. Upload your deck and get matched with investors who actually fit your startup — so you can focus on building, not chasing.
